Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Neoplasms 3Lung Neoplasms 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Pleural Neoplasms 1Pancreatic Cyst 1Mesothelioma 1Glioma 1Glioblastoma 1Disease 1Breast Neoplasms 1Brain Neoplasms 1Astrocytoma 1

Interventions

Cisplatin 32human papillomavirus vaccine, L1 type 16, 18 16Brachytherapy 15Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 12Paclitaxel 11Bevacizumab 11pembrolizumab 10Platinum 91,2-diaminocyclohexaneplatinum II citrate 9Topotecan 8Radiotherapy, Intensity-Modulated 8Radiation 8Papillomavirus Vaccines 8atezolizumab 6Gemcitabine 6Fluorodeoxyglucose F18 6Cyclophosphamide 6tisotumab vedotin 5fludarabine phosphate 5fludarabine 5aldesleukin 5Taxes 5Radiotherapy 5Magnetic Resonance Spectroscopy 5Carboplatin 5Vaccines, Synthetic 4Nivolumab 4Immunoglobulin G 4Disulfides 4Colposcopy 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Uterine Cervical Neoplasms × Drug Delivery Systems × Clear all
NCT01851772 2021-01-12

Feasibility Study of the Xoft® Axxent® Electronic Brachytherapy System for the Treatment of Cervical Cancer

Xoft, Inc.

Phase NA Completed
3 enrolled 6 charts
Gynecologic

Uterine Cervical Neoplasms, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡